https://ir.ibioinc.com/ https://ir.ibioinc.com/company-info https://ir.ibioinc.com/company-info/executive-team https://ir.ibioinc.com/company-info/presentations https://ir.ibioinc.com/company-info/contacts https://ir.ibioinc.com/company-info/faq https://ir.ibioinc.com/news-events https://ir.ibioinc.com/news-events/press-releases https://ir.ibioinc.com/news-events/ir-calendar https://ir.ibioinc.com/news-events/email-alerts https://ir.ibioinc.com/financials https://ir.ibioinc.com/stock-data https://ir.ibioinc.com/stock-data/historical-data https://ir.ibioinc.com/stock-data/analyst-coverage https://ir.ibioinc.com/sec-filings/all-sec-filings https://ir.ibioinc.com/sec-filings/annual-reports https://ir.ibioinc.com/sec-filings/quarterly-reports https://ir.ibioinc.com/sec-filings/section-16-filings https://ir.ibioinc.com/sec-filings/current-reports https://ir.ibioinc.com/corporate-governance https://ir.ibioinc.com/corporate-governance/board-of-directors https://ir.ibioinc.com/corporate-governance/board-committees https://ir.ibioinc.com/corporate-governance/governance-documents https://ir.ibioinc.com/news-events/press-releases/detail/256/ibio-to-provide-an-update-on-cardiopulmonary-program-targeting-pulmonary-hypertension-associated-with-heart-failure-with-preserved-ejection-fraction-ph-hfpef 2026-03-16T16:30:03-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/255/ibio-reports-preclinical-body-composition-data-from-obese-non-human-primates-treated-with-ibio-610-a-potential-first-in-class-treatment-for-fat-selective-weight-loss 2026-03-09T07:00:02-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/254/ibio-to-participate-in-upcoming-investor-conferences 2026-02-24T07:00:03-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/253/ibio-reports-q2-fiscal-year-2026-financial-results-and-provides-corporate-update 2026-02-10T16:05:03-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/252/ibio-announces-26-million-private-placement 2026-01-09T07:00:03-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/251/ibio-to-participate-in-the-8th-annual-evercore-healthcare-conference 2025-11-24T16:15:01-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/250/ibio-reports-q1-fiscal-year-2026-financial-results-and-provides-corporate-update 2025-11-12T16:01:05-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/249/ibio-unveils-new-non-human-primate-data-on-ibio-610-an-activin-e-antibody-with-strong-therapeutic-potential-for-fat-selective-weight-loss-and-weight-maintenance 2025-10-30T07:00:10-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/248/ibio-to-participate-in-the-guggenheim-2nd-annual-healthcare-innovation-conference 2025-10-23T07:00:10-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/247/ibio-to-present-new-preclinical-data-on-its-activin-e-antibody-at-two-upcoming-scientific-conferences-obesityweek-and-pegs-europe-2025 2025-10-21T07:00:07-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/246/ibio-reports-fiscal-year-2025-financial-results-and-provides-corporate-update 2025-09-05T07:30:03-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/245/ibio-announces-closing-of-50-million-public-offering 2025-08-25T07:00:06-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/244/ibio-announces-pricing-of-50-million-public-offering 2025-08-19T08:01:19-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/243/ibio-announces-proposed-public-offering 2025-08-18T16:01:03-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/242/ibio-and-astralbio-unveil-obesity-program-with-novel-amylin-agonist-antibody-demonstrating-promising-in-vivo-results 2025-06-24T07:00:09-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/241/ibio-presents-next-generation-obesity-and-cardiometabolic-pipeline-candidates-on-june-24-conference-call 2025-06-23T16:15:01-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/240/ibio-initiates-non-human-primate-study-of-first-in-class-activin-e-antibody-following-positive-preclinical-data-demonstrating-prevention-in-weight-regain-after-glp-1-treatment 2025-06-16T07:00:03-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/239/ibios-first-in-class-activin-e-antibody-achieves-26-fat-reduction-without-muscle-loss-and-shows-synergy-with-glp-1s-in-preclinical-model 2025-05-05T08:00:17-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/238/ibio-reports-fiscal-third-quarter-2025-financial-results 2025-05-02T08:00:05-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/237/ibio-raises-6-2-million-through-warrant-inducement-transaction 2025-04-29T13:43:31-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/236/ibio-expands-cardiometabolic-and-obesity-pipeline-through-licensing-of-first-in-class-antibody-targeting-activin-e-from-astralbio 2025-04-22T08:00:04-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/235/ibio-announces-ibio-600-non-human-primate-data-showing-extended-half-life-and-muscle-growth-and-interim-in-vivo-results-for-first-in-class-activin-e-antibody-advancing-cardiometabolic-and-obesity-pipeline 2025-04-07T07:00:03-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/234/ibio-to-begin-trading-on-the-nasdaq-stock-exchange 2025-02-19T16:05:23-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/233/ibio-reports-fiscal-second-quarter-2025-financial-results 2025-02-10T16:05:02-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/232/ibio-announces-new-investments-from-board-members-and-officers 2025-01-13T07:00:30-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/231/ibio-discovers-novel-antibody-targeting-activin-e-in-collaboration-with-astralbio 2025-01-07T07:00:38-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/230/ibio-expands-cardiometabolic-and-obesity-program-with-anti-myostatin-antibody-discovered-using-its-proprietary-platform-in-licensed-from-astralbio 2025-01-02T07:00:33-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/229/ibio-strengthens-board-with-appointment-of-two-new-independent-directors 2024-11-25T08:00:16-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/228/ibio-reports-fiscal-first-quarter-2025-financial-results 2024-11-12T16:05:18-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/227/ibio-and-astralbio-provide-update-on-myostatin-program-for-obesity 2024-10-10T08:00:57-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/226/ibio-reports-fiscal-year-2024-financial-results-and-provides-corporate-update 2024-09-20T16:05:03-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/225/ibio-to-participate-in-upcoming-investor-conferences 2024-09-03T07:00:13-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/224/ibio-expands-executive-leadership-team-with-appointment-of-kristi-sarno-as-senior-vice-president-of-business-development 2024-08-12T16:30:10-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/223/ibio-closes-sale-of-manufacturing-facility-in-texas 2024-06-03T07:00:03-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/222/ibio-reports-fiscal-third-quarter-2024-financial-results-and-provides-corporate-update 2024-05-13T16:05:18-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/221/ibio-and-astralbio-announce-transformative-ai-drug-discovery-collaboration-to-rapidly-develop-novel-antibodies-for-obesity-and-cardiometabolic-diseases 2024-03-27T07:00:02-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/220/ibio-announces-15-0-million-private-placement 2024-03-26T19:35:12-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/219/ibio-announces-sale-of-preclinical-pd-1-agonist-antibody-program-to-otsuka 2024-02-26T07:45:01-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/218/ibio-announces-participation-in-23rd-annual-peptalk-conference 2024-01-16T08:15:01-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/217/ibio-amends-and-extends-maturity-of-credit-agreement 2023-12-26T07:15:02-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/216/ibio-inc-announces-pricing-of-4-5-million-public-offering 2023-12-05T08:00:04-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/215/ibio-announces-reverse-stock-split 2023-11-27T17:20:01-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/214/ibio-further-expands-tech-stack-with-shieldtx-enhances-immuno-oncologydevelopment-pipeline-with-conditionally-activated-muc16xcd3-bispecific 2023-11-01T08:24:01-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/213/ibio-to-highlight-technology-for-advancing-discovery-of-bispecifics-at-festival-of-biologics 2023-10-10T08:00:01-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/212/ibio-explains-recent-filing-of-registration-statement 2023-10-02T06:45:02-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/211/ibio-announces-filing-of-2023-annual-report-on-sec-form-10-k 2023-09-27T16:19:29-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/210/ibio-announces-amendment-to-credit-agreement-with-woodforest 2023-09-22T11:07:29-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/209/ibio-reports-triple-milestone-in-vivo-proof-of-concept-for-three-programs-a-transformative-step-in-advancing-its-immuno-oncology-pre-clinical-pipeline-towards-clinical-development 2023-08-14T16:15:01-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/208/ibio-appoints-dr-martin-brenner-as-ceo-felipe-duran-as-cfo-to-oversee-companys-next-stage-of-growth 2023-06-27T08:00:07-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/207/ibio-forges-research-collaboration-with-the-national-institutes-of-health 2023-06-12T16:15:01-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/206/ibio-expands-tech-stack-with-engagetx-adds-trop-2-bispecific-to-development-pipeline 2023-06-06T08:00:02-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/205/ibio-to-participate-in-the-jmp-securities-life-sciences-conference 2023-05-09T16:30:04-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/204/ibio-discovers-new-panel-of-cd3-t-cell-binding-antibodies-using-its-patented-ai-epitope-steering-platform 2023-04-04T16:05:05-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/203/ibio-advances-anti-ccr8-antibody-program-to-preclinical-in-vivo-testing 2023-03-31T08:10:02-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/202/ibio-announces-muc16-as-its-latest-immune-oncology-target-program 2023-02-16T16:48:00-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/201/ibio-announces-issuance-of-u-s-patent-covering-ai-engineered-epitope-discovery-engine 2023-01-05T08:00:03-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/200/ibio-announces-closing-of-3-5-million-underwritten-public-offering 2022-12-09T16:05:02-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/199/ibio-announces-pricing-of-3-5-million-underwritten-public-offering 2022-12-06T23:27:47-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/198/ibio-announces-proposed-underwritten-public-offering 2022-12-06T16:01:03-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/197/ibio-to-participate-in-the-jmp-securities-hematology-and-oncology-summit 2022-12-06T08:00:12-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/196/ibio-to-showcase-the-rubryc-discovery-engine-during-poster-presentations-at-antibody-engineering-therapeutics-conference-2022 2022-12-05T08:00:02-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/195/ibio-announces-ceo-departure 2022-12-02T16:30:02-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/194/ibio-accelerates-transformation-to-ai-powered-biotech 2022-11-03T08:00:15-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/193/ibio-reports-preliminary-unaudited-fiscal-year-2022-financial-results-and-provides-corporate-update 2022-09-27T16:10:01-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/192/ibio-acquires-rubryc-therapeutics-ai-drug-discovery-platform-and-pipeline 2022-09-21T08:30:08-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/191/ibio-provides-update-on-development-of-next-gen-covid-19-vaccine-candidate 2022-08-16T09:00:10-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/190/ibio-to-participate-in-the-h-c-wainwright-global-investment-conference 2022-05-18T08:00:14-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/189/ibio-reports-fiscal-third-quarter-2022-financial-results-and-provides-corporate-update 2022-05-12T16:24:33-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/188/ibio-demonstrates-efficacy-of-an-il-2-sparing-anti-cd25-antibody-produced-using-its-fastpharming-system-for-treg-depletion-in-cancer 2022-05-09T12:48:24-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/187/ibio-to-report-fiscal-2022-third-quarter-financial-results-and-provide-corporate-update-on-thursday-may-12-2022 2022-05-05T16:30:03-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/186/ibio-announces-presentation-highlighting-superior-glycosylation-for-antibodies-produced-in-plants 2022-05-02T15:38:13-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/185/ibio-to-participate-in-the-oppenheimer-32nd-annual-healthcare-conference 2022-03-11T08:00:02-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/184/ibio-reports-fiscal-second-quarter-2022-financial-results-and-provides-corporate-update 2022-02-14T16:05:06-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/183/ibio-to-report-fiscal-2022-second-quarter-financial-results-and-provide-corporate-update-on-monday-february-14-2022 2022-02-07T16:30:02-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/182/ibio-announces-progression-of-vaccine-program-for-multi-variant-covid-19-disease 2022-01-26T09:00:04-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/181/ibio-announces-participation-in-the-h-c-wainwright-bioconnect-conference 2022-01-04T16:30:02-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/180/ibio-announces-partial-adjournment-of-annual-meetingof-shareholders-to-january-31-2022 2021-12-22T09:25:01-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/179/ibio-provides-information-for-listening-to-the-virtual-annual-stockholder-meeting 2021-12-21T09:20:01-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/178/ibio-announces-partial-adjournment-of-annual-meetingto-december-22 2021-12-10T08:30:01-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/177/iss-joins-glass-lewis-in-recommending-shareholders-vote-for-all-proposals-ahead-of-ibios-upcoming-annual-meeting 2021-11-30T08:00:03-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/176/omicron-variant-underscores-need-for-new-covid-vaccine-candidates-like-ibio-202 2021-11-29T08:45:02-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/175/leading-independent-proxy-advisory-firm-glass-lewis-recommends-ibio-shareholders-vote-for-all-proposals-ahead-of-annual-meeting 2021-11-17T16:30:01-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/174/ibio-reports-fiscal-first-quarter-2022-financial-results-and-provides-corporate-update 2021-11-15T16:05:48-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/173/ibio-announces-collaboration-with-ut-southwestern-to-investigate-ibio-100-in-solid-tumors 2021-11-15T13:00:01-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/172/ibio-to-report-fiscal-2022-first-quarter-financial-results-and-provide-corporate-update-on-monday-november-15-2021 2021-11-08T16:30:02-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/171/ibio-acquires-fastpharming-manufacturing-facility 2021-11-03T16:47:07-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/170/ibio-urges-shareholders-to-vote-for-all-proposals-ahead-of-its-upcoming-annual-meeting-to-be-held-on-december-9 2021-10-26T08:35:01-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/169/ibio-reports-fourth-quarter-and-fiscal-year-2021-financial-results-and-provides-corporate-update 2021-09-27T07:30:03-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/168/ibio-to-participate-in-the-cantor-2021-virtual-global-healthcare-conference 2021-09-20T16:30:03-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/167/ibio-to-report-fiscal-fourth-quarter-and-full-year-2021-financial-results-and-provide-corporate-update-on-monday-september-27-2021 2021-09-20T07:30:02-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/166/ibio-announces-participation-in-h-c-wainwright-23rd-annual-global-investment-conference 2021-09-07T16:30:04-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/165/ibio-appoints-william-d-clark-to-its-board-of-directors 2021-08-26T07:00:01-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/164/ibio-expands-immuno-oncology-pipeline-in-ai-partnership-with-rubryc-therapeutics 2021-08-25T07:30:02-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/163/ibio-reports-successful-preclinical-immunization-studies-with-next-gen-nucleocapsid-covid-19-vaccine-candidate 2021-07-15T17:10:01-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/162/ibio-establishes-oncology-drug-discovery-pipeline-with-three-new-antibody-programs 2021-07-08T16:15:02-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/161/ibio-further-strengthens-board-with-appointment-of-veteran-biopharmaceutical-executive-eef-schimmelpennink 2021-06-09T16:30:07-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/160/ibio-to-present-at-the-ubs-global-healthcare-virtual-conference 2021-05-19T16:30:02-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/159/ibio-reports-fiscal-third-quarter-2021-financial-results-and-provides-corporate-update 2021-05-17T07:00:24-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/158/ibio-to-report-fiscal-2021-third-quarter-financial-results-and-provide-corporate-update-on-monday-may-17-2021 2021-05-10T08:15:02-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/157/ibio-reports-successful-covid-19-vaccine-toxicology-study-results-and-announces-next-gen-covid-19-vaccine-program 2021-05-06T16:15:06-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/156/ibio-and-fraunhofer-usa-conclude-litigation-and-enter-license-agreement 2021-05-04T17:00:01-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/155/ibio-to-participate-in-the-33rd-annual-roth-conference 2021-03-09T16:30:01-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/154/ibio-reports-fiscal-second-quarter-2021-financial-results-and-provides-corporate-update 2021-02-16T16:05:03-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/153/ibio-appoints-robert-m-lutz-as-chief-financial-business-officer 2021-02-16T08:00:17-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/152/ibio-to-report-fiscal-2021-second-quarter-financial-results-and-provide-corporate-update-on-tuesday-february-16-2021 2021-02-09T16:30:01-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/151/ibio-appoints-dr-martin-b-brenner-as-chief-scientific-officer 2020-12-31T11:57:52-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/150/ibio-announces-closing-of-its-public-offering-of-common-stock 2020-12-10T16:30:00-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/149/ibio-announces-pricing-of-35-million-public-offering-of-common-stock 2020-12-08T08:55:00-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/148/ibio-announces-proposed-public-offering-of-common-stock 2020-12-07T16:01:01-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/147/ibio-selected-to-produce-atb-therapeutics-bioengineered-antibody-toxin-fusion-proteins 2020-12-01T16:30:00-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/146/ibio-announces-issuance-of-u-s-patent-covering-endostatin-peptides-for-treating-fibrosis 2020-11-24T07:30:02-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/145/ibio-reports-fiscal-first-quarter-2021-financial-results-and-provides-corporate-update 2020-11-16T16:05:05-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/144/ibio-to-participate-in-alliance-global-partners-virtual-healthcare-symposium 2020-11-12T08:00:07-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/143/ibio-to-report-fiscal-2021-first-quarter-financial-results-and-provide-corporate-update-on-monday-november-16-2020 2020-11-05T16:30:02-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/142/ibio-announces-appointment-of-randy-j-maddux-as-chief-operating-officer 2020-11-03T07:30:02-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/141/accomplished-financial-executive-gary-sender-joins-ibios-board-of-directors 2020-10-15T16:05:09-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/140/ibio-announces-appointment-of-dr-alexandra-kropotova-to-board-of-directors 2020-10-15T07:30:08-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/139/ibio-announces-appointment-of-dr-linda-armstrong-to-board-of-directors 2020-10-14T16:05:09-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/138/ibio-announces-financial-results-for-fiscal-year-ended-june-30-2020 2020-10-13T16:05:08-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/137/ibio-regains-compliance-with-nyse-american-continued-listing-standards 2020-10-05T07:30:08-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/136/ibio-enters-into-agreement-with-safi-biosolutions-to-develop-growth-factors-and-cytokines-using-the-fastpharming-system 2020-10-02T06:59:38-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/135/ibio-to-advance-covid-19-lickm-subunit-vaccine-candidate-ibio-201 2020-09-09T08:45:03-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/134/ibio-and-planet-biotechnology-enter-into-exclusive-worldwide-license-agreement-for-the-development-of-a-covid-19-therapeutic 2020-08-28T07:15:04-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/133/ibio-provides-update-on-ibio-201-covid-19-vaccine-program 2020-08-10T07:15:04-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/132/ibio-to-be-added-to-the-russell-2000-and-russell-3000-indexes 2020-06-26T06:45:03-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/131/ibio-selected-by-ibm-watson-health-for-the-use-of-ibm-clinical-development-solution-at-no-cost-to-help-support-clinical-covid-19-vaccine-candidates 2020-06-24T06:45:03-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/130/ibio-announces-second-covid-19-vaccine-program 2020-06-04T07:00:11-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/129/ibio-estimates-~500-million-dose-capacity-for-covid-19-vaccine-from-its-fastpharming-facility 2020-04-27T16:15:08-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/128/ibio-expands-covid-19-vaccine-collaboration-to-include-the-infectious-disease-research-institute 2020-04-09T07:30:07-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/127/ibio-supporting-azargen-biotechnologies-development-of-a-rituximab-biosimilar 2020-03-26T16:20:27-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/126/ibio-announces-advancement-of-covid-19-vaccine-program 2020-03-26T07:30:05-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/125/ibio-joins-the-alliance-for-biosecurity 2020-03-20T07:30:06-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/124/ibio-announces-development-of-proprietary-covid-19-vaccine-candidates 2020-03-18T08:00:11-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/123/ibio-announces-leadership-succession-appoints-thomas-f-isett-co-chairman-ceo 2020-03-12T16:45:05-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/122/ibio-inc-announces-withdrawal-of-proxy-statement-proposal-to-amend-its-certificate-of-incorporation-to-authorize-a-possible-reverse-stock-split 2020-03-02T16:30:07-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/121/ibio-inc-announces-postponement-of-annual-meeting 2020-02-06T16:30:05-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/120/ibio-and-cc-pharming-initiate-joint-development-of-coronavirus-vaccine 2020-02-03T16:15:07-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/119/ibio-inc-announces-nyse-american-acceptance-of-plan-of-compliance 2020-01-16T08:00:13-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/118/ibio-initiates-new-litigation-against-fraunhofer 2020-01-06T09:15:04-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/117/ibio-announces-collaboration-with-edgepoint-ai-for-next-gen-quality-in-biologics-manufacturing 2019-12-23T08:30:07-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/116/ibio-reports-progress-on-its-bio-better-rituximab-collaboration-with-cc-pharming 2019-12-16T16:15:08-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/115/ibio-inc-reports-on-nyse-american-noncompliance-notice-and-compliance-plan 2019-12-13T17:00:08-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/114/ibio-introduces-fastglycaneering-development-service-to-power-recombinant-protein-production 2019-12-10T16:43:45-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/113/ibio-joins-manufacturing-usas-tissue-biofabrication-initiative 2019-12-03T12:31:03-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/112/ibio-to-present-at-the-first-annual-biotuesdays-pre-jpm-virtual-conference 2019-12-03T11:16:41-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/111/ibio-inc-prices-5000000-public-offering 2019-10-25T08:30:10-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/110/ibio-inc-reports-on-nyse-american-noncompliance-notice-and-compliance-plan 2019-10-22T16:30:10-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/109/ibios-collaboration-with-south-africas-azargen-biotechnologies-advances-to-next-stage 2019-09-17T16:15:03-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/108/ibio-and-cc-pharming-expand-business-collaboration-in-china 2019-08-26T17:30:02-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/107/ibio-inks-3d-bioprinting-agreement 2019-08-19T16:35:01-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/106/ibio-announces-first-agreement-for-fill-finish-services 2019-06-19T08:00:36-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/105/ibio-launches-new-sterile-fill-finish-services 2019-06-03T08:00:41-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/104/ibio-announces-appointment-of-thomas-f-isett-to-board-of-directors 2019-04-01T08:30:14-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/103/ibio-provides-status-update-on-its-continuing-litigation-against-fraunhofer 2018-12-14T08:00:06-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/102/ibio-to-present-at-brazilian-ministry-of-healths-plant-made-pharmaceutical-meeting 2018-12-03T08:00:19-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/101/ibio-and-cc-pharming-hold-first-design-and-strategy-meeting 2018-10-02T08:00:10-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/100/ibio-inc-announces-nyse-american-acceptance-of-plan-of-compliance 2018-08-22T16:10:03-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/99/ibio-establishes-strategic-commercial-relationship-with-cc-pharming-ltd-of-beijing-china 2018-07-09T08:00:09-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/98/ibio-inc-closes-16000000-public-offering 2018-06-26T18:58:40-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/97/ibio-inc-prices-16000000-public-offering 2018-06-22T07:26:18-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/96/ibio-inc-announces-completion-of-1-for-10-reverse-stock-split 2018-06-08T16:30:03-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/95/ibio-inc-reports-on-nyse-american-noncompliance-notice-and-compliance-plan 2018-06-08T16:01:03-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/94/ibio-and-oneway-diagnostica-develop-new-products-for-brazil 2018-06-05T08:30:10-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/93/ibio-inc-announces-reverse-stock-split 2018-05-31T08:30:06-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/92/ibio-selects-lead-candidate-for-its-fibrosis-therapeutics-program 2018-03-14T08:30:06-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/91/ibio-patent-issues-in-china-on-protein-glycosylation-modification 2018-03-12T08:34:54-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/90/ibio-expands-antibody-development-and-production-services-to-include-fc-fusion-therapeutics 2018-03-07T08:45:02-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/89/ibio-inc-provides-corporate-update 2018-01-05T17:00:03-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/88/ibio-inc-closes-4500000-offering-of-common-stock 2017-11-30T16:15:03-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/87/ibio-inc-prices-4500000-firm-commitment-offering-of-common-stock 2017-11-29T09:00:10-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/86/ibio-inc-announces-proposed-public-offering-of-common-stock 2017-11-28T17:06:49-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/85/ibio-inc-initiates-litigation-against-fraunhofer-gesellschaft-in-delaware-chancery-court 2017-11-07T17:46:22-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/84/ibio-cdmo-president-to-co-chair-south-african-molecular-pharming-conference 2017-10-30T08:30:05-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/83/ibio-announces-manufacturing-collaboration-with-aethlon-medical 2017-10-16T08:41:42-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/82/ibio-appoints-james-abbey-ph-d-as-vice-president-of-strategic-business-development 2017-10-02T08:31:38-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/81/ibio-inc-intellectual-property-update 2017-09-20T08:00:08-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/80/ibio-makes-nyse-mkt-section-610b-public-announcement 2017-09-19T17:55:22-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/79/ibio-and-theoremdx-collaborate-to-develop-proteins-for-rapid-diagnostics-testing-products 2017-09-18T08:01:34-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/78/ibio-inc-enters-into-common-stock-purchase-agreement-for-up-to-16-0-million-with-lincoln-park-capital 2017-07-24T08:30:04-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/77/ibio-inc-to-present-plant-made-pharmaceutical-platform-at-plant-based-vaccines-antibodies-biologics-conference 2017-06-05T08:30:04-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/76/ibio-inc-provides-corporate-update-at-annual-shareholders-meeting 2017-05-04T16:01:01-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/75/court-schedules-hearing-to-consider-approval-of-settlement-of-derivative-action 2017-01-27T08:30:01-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/74/another-ibio-plague-vaccine-patent-issues 2016-11-21T08:31:00-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/73/ibio-expands-product-development-capacity-of-cgmp-plant 2016-11-10T08:31:00-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/72/ibio-proprietary-technology-advances-neonatal-respiratory-distress-syndrome-drug-development-for-south-african-biotech-company-azargen-biotechnologies-pty-ltd 2016-09-29T08:30:02-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/71/implications-of-court-decision-in-favor-of-ibio-against-fraunhofer 2016-08-15T08:30:03-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/70/ibio-inc-s-claims-against-fraunhofer-affirmed-by-delaware-chancery-court 2016-08-04T08:31:01-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/69/ibio-inc-receives-fda-orphan-drug-designation-for-fibrosis-product-candidate 2016-07-05T08:31:00-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/68/ibio-inc-receives-new-patent-for-its-biotherapeutic-products-for-treatment-of-fibrosis 2016-06-29T10:16:27-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/67/texas-am-university-system-and-ibio-execute-joint-development-agreement-for-plant-produced-pharmaceuticals 2016-06-07T08:31:00-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/66/ibio-inc-holds-annual-meeting-in-college-station-texas 2016-04-07T17:46:58-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/65/ibio-forms-joint-venture-cmo-for-large-scale-pharmaceuticals-manufacturing-in-green-plants-and-accepts-additional-investment 2016-01-14T09:00:17-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/64/ibio-continues-global-expansion-of-intellectual-property 2015-11-30T08:31:00-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/63/scientific-insights-into-ibio-cfb03-presented-at-american-college-of-rheumatology-annual-meeting 2015-11-19T08:31:00-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/62/ibio-european-protein-expression-patent-emerges-from-opposition-period 2015-10-27T08:31:00-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/61/new-chinese-ibiomodulatortm-patent-joins-ibio-vaccine-portfolio 2015-09-30T08:31:00-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/60/ibio-anti-fibrosis-portfolio-expanded-to-include-orally-delivered-peptides 2015-09-21T08:31:00-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/59/ibio-fibrosis-therapeutics-program-receives-nih-grant-support 2015-09-09T08:31:02-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/58/ibio-to-receive-us-patent-for-influenza-therapeutic 2015-08-11T08:31:21-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/57/three-recent-ibiolaunchtm-platform-achievements-to-be-presented-at-pbvab-2015-conference-in-lausanne-switzerland 2015-06-08T08:31:00-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/56/vaccine-improvement-patent-awarded-to-ibio 2015-05-04T08:31:00-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/55/ibio-arranges-production-of-ibio-cfb03-for-clinical-development-with-caliber-biotherapeutics 2015-04-27T08:31:00-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/54/ibio-european-plague-vaccine-patent-emerges-from-opposition-period 2015-03-30T08:31:01-04:00 https://ir.ibioinc.com/news-events/press-releases/detail/44/ibio-adds-anthrax-antibodies-to-product-pipeline 2015-02-25T08:31:00-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/34/ibio-receives-us-and-european-patents-for-protein-expression-technology 2015-02-12T08:31:00-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/24/ibio-adds-to-ibiomodulator-portfolio-and-product-pipeline 2015-02-04T08:33:14-05:00 https://ir.ibioinc.com/news-events/press-releases/detail/14/ibio-provides-updates-on-its-ibio-cfb03-fibrosis-drug-candidate-and-other-activities-for-the-2014-annual-shareholders-meeting 2014-12-10T08:31:00-05:00 https://ir.ibioinc.com/news-events/ir-calendar/detail/20260317-ibio-provides-update-on-cardiopulmonary-program-targeting-ph-hfpef 2026-03-16T16:31:45-04:00 https://ir.ibioinc.com/news-events/ir-calendar/detail/20260309-leerink-global-healthcare-conference 2026-01-26T17:58:51-05:00 https://ir.ibioinc.com/news-events/ir-calendar/detail/20260226-oppenheimer-36th-annual-healthcare-life-sciences-conference 2026-01-26T17:57:36-05:00 https://ir.ibioinc.com/sec-filings/all-sec-filings/content/0001104659-26-036093/tm269997-1_4seq1.html 2026-03-27T16:12:43-04:00 https://ir.ibioinc.com/sec-filings/all-sec-filings/content/0001104659-26-033028/tm269462-2_4seq1.html 2026-03-23T07:31:43-04:00 https://ir.ibioinc.com/sec-filings/all-sec-filings/content/0001104659-26-033021/tm269462-1_4seq1.html 2026-03-23T07:30:55-04:00 https://ir.ibioinc.com/sec-filings/all-sec-filings/content/0001420720-26-000006/ibio-20260309x8k.htm 2026-03-09T07:05:40-04:00 https://ir.ibioinc.com/sec-filings/all-sec-filings/content/9999999995-26-000750/primary_doc.html 2026-03-09T06:03:11-04:00 https://ir.ibioinc.com/sec-filings/all-sec-filings/content/0001104659-26-024795/tm267370d2_424b5.htm 2026-03-06T17:28:03-05:00 https://ir.ibioinc.com/sec-filings/all-sec-filings/content/0001104659-26-023517/filename1.htm 2026-04-03T10:44:40-04:00 https://ir.ibioinc.com/sec-filings/all-sec-filings/content/0000000000-26-002235/0000000000-26-002235.pdf 2026-04-03T10:44:36-04:00 https://ir.ibioinc.com/sec-filings/all-sec-filings/content/0001104659-26-021654/tm267467d1_8k.htm 2026-02-27T16:52:12-05:00 https://ir.ibioinc.com/sec-filings/all-sec-filings/content/0001104659-26-021610/tm267370d1_s3.htm 2026-02-27T16:34:02-05:00 https://ir.ibioinc.com/sec-filings/all-sec-filings/content/0001104659-26-016622/primary_doc.html 2026-02-17T18:21:18-05:00 https://ir.ibioinc.com/sec-filings/all-sec-filings/content/0000935836-26-000115/primary_doc.html 2026-02-17T18:20:00-05:00 https://ir.ibioinc.com/sec-filings/all-sec-filings/content/0000902664-26-001049/primary_doc.html 2026-02-17T13:47:08-05:00 https://ir.ibioinc.com/company-info/presentations/detail/5111/investor-presentation 2026-03-09T00:00:00-04:00 https://ir.ibioinc.com/disclaimer https://ir.ibioinc.com/sitemap